Related Experiment Videos
Differences between plasma and serum complement in patients with chronic liver disease
Insights
Chronic liver disease patients with cirrhosis showed low serum complement levels (CH50), indicating early complement component activation during blood coagulation. This finding was specific to serum, not plasma, in these patients.
Area of Science:
- Immunology
- Hepatology
- Biochemistry
Background:
- Chronic liver disease, including cirrhosis and chronic hepatitis, can affect immune system function.
- The complement system is a crucial part of innate immunity, involving a cascade of proteins.
Purpose of the Study:
- To investigate complement component levels in patients with chronic liver disease.
- To explore potential differences between serum and plasma complement activity in this patient group.
Main Methods:
- Serum and plasma total complement activity (CH50) were measured.
- Complement component profiles, including C2, C3, C4, and C3-C9, were analyzed in patients with low serum CH50.
- Patients with hepatitis B surface antigen were also assessed for CH50 differences.
Main Results:
- Eight out of sixty chronic liver disease patients with cirrhosis or chronic hepatitis exhibited significantly low serum CH50 but normal plasma CH50.
- These patients displayed markedly decreased C4 and C2 complement activities, with normal C3-C9 activities.
- No significant difference in serum versus plasma CH50 was observed in patients with hepatitis B surface antigen.
Conclusions:
- Early-acting complement components (C4, C2) may be non-specifically activated during blood coagulation in some chronic liver disease patients.
- Serum CH50 levels can be a more sensitive indicator than plasma CH50 in specific chronic liver disease contexts.
- Further research is needed to elucidate the precise mechanisms of complement activation in chronic liver disease.
Abstract:
Of sixty patients with chronic liver disease, eight with cirrhosis or chronic hepatitis had very low serum CH50 but normal plasma CH50. The complement component profiles of these sera revealed markedly decreased C4 and C2 activities and normal C3T (C3-C9) activities. From these results, it is suggested that the early acting complement components had been non-specifically activated during blood coagulation in these patients. No difference between plasma and serum CH50 was found in patients with hepatitis B(s) antigen.